Apellis Pharmaceuticals (APLS) Prices 9.5M Share Offering at $37/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- US stock futures tumble as Trump says Iran deal is 'over', oil climbs
- Oil jumps over 5% to two-week high after Trump says deal with Iran 'over'
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Amazon launches bond sale seeking at least $25 billion
- Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
Apellis Pharmaceuticals (APLS) PT Raised to $62 at Oppenheimer
January 8, 2020 9:25 AM ESTOppenheimer analyst Justin Kim raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $62.00 (from $52.00) while maintaining a Outperform rating.
The analyst commented, "We are reiterating our Outperform rating and increasing our PT to $62 on APLS, following positive Phase 3 PEGASUS data in PNH... More
Apellis Pharmaceuticals (APLS) PT Raised to $80 at Citi
January 8, 2020 6:08 AM ESTCiti analyst Yigal Nochomovitz raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $80.00 (from $37.00) while maintaining a Buy rating.... More
Apellis Pharmaceuticals (APLS) PT Raised to $36 at Credit Suisse
January 8, 2020 6:03 AM ESTCredit Suisse analyst Tiago Fauth raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $36.00 (from $33.00) while maintaining a Neutral rating.... More
Apellis Pharmaceuticals (APLS) PT Raised to $36 at Credit Suisse
January 7, 2020 4:17 PM ESTCredit Suisse analyst Tiago Fauth raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $36.00 (from $33.00) while maintaining a Neutral rating.
The analyst comments "Todays PEGASUS efficacy data came in ahead of investors expectations, though it doesnt meaningfully change our view on... More
Apellis Pharmaceuticals (APLS) Announces Proposed 7M Share Common Offering
January 7, 2020 4:13 PM ESTApellis Pharmaceuticals, Inc. (NASDAQ: APLS) today announced that it has commenced an underwritten public offering of 7,000,000 shares of its common stock. All of the shares are being offered by Apellis. In addition, Apellis expects to grant the underwriters a 30-day option to... More
Apellis Pharmaceuticals (APLS) files automatic mixed securities shelf
January 7, 2020 4:05 PM ESTApellis Pharmaceuticals (NASDAQ: APLS) files automatic mixed securities shelf
... MoreApellis Pharmaceuticals (APLS) PT Raised to $62 at Oppenheimer
January 7, 2020 3:26 PM ESTOppenheimer analyst Justin Kim raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $62.00 (from $52.00) while maintaining a Outperform rating.
... MoreApellis Pharmaceuticals (APLS) PT Raised to $80 at Citi
January 7, 2020 2:57 PM ESTCiti analyst Yigal Nochomovitz raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $80.00 (from $37.00) while maintaining a Buy rating.
... MorePre-Open Stock Movers 01/07: (APLS) (TYME) (APA) Higher (CRNC) (ITCI) (ARE) Lower (more...)
January 7, 2020 9:30 AM ESTToday's Pre-Open Stock Movers
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) 36.8% HIGHER; Announced positive results from the Phase 3 PEGASUS study evaluating pegcetacoplan (APL-2) in adults with paroxysmal nocturnal hemoglobinuria (PNH). Top-line data show that pegcetacoplan met the studys primary efficacy endpoint, demonstrating... More
Apellis Pharmaceuticals (APLS) PT Raised to 'Street High' $70 at Baird
January 7, 2020 9:08 AM ESTBaird analyst Brian Skorney raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to a 'Street High' $70.00 (from $45.00) while maintaining a Outperform rating.
... MoreApellis Pharmaceuticals (APLS) Data Exceeded Expectations, Expect Shares to Fly - Cantor Fitzgerald
January 7, 2020 8:08 AM ESTCantor Fitzgerald analyst Eliana Merle reiterated an Overweight rating and $54.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS) following positive data.
Merle commented, "We think positive Ph3 data well exceeds investor expectations. As we wrote in our preview (link), we think investors... More
Alexion Pharma (ALXN) Shares on Watch After Positive Data from Competitor Apellis Pharmaceuticals (APLS) in PNH
January 7, 2020 7:10 AM ESTAlexion Pharma (NASDAQ: ALXN) Shares on Watch After Positive Data from Competitor Apellis Pharmaceuticals (NASDAQ: APLS) in PNH
... MoreApellis Pharmaceuticals (APLS) to Resume Trading at 7:30 am
January 7, 2020 7:07 AM ESTApellis Pharmaceuticals (NASDAQ: APLS) to Resume Trading at 7:30 am
... MoreApellis Pharmaceuticals (APLS) Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with PNH Met the Primary Efficacy Endpoint
January 7, 2020 7:01 AM ESTApellis... More
Apellis Pharmaceuticals (APLS) Halted, News Pending
January 7, 2020 6:58 AM ESTApellis Pharmaceuticals (NASDAQ: APLS) Halted, News Pending
... MoreSVB Leerink Starts Apellis Pharmaceuticals (APLS) at Market Perform
January 7, 2020 6:12 AM ESTSVB Leerink analyst Dae Gon Ha initiates coverage on Apellis Pharmaceuticals (NASDAQ: APLS) with a Market Perform rating and a price target of $30.00.
For an analyst ratings summary and ratings history on Apellis Pharmaceuticals... More
